Leitlinien Onkologie Hub
  • Close Guideline
  • 1Information about this Guideline
  • 2Introduction
  • 3Prevention Asymptomatic Population
  • 4Screening Asymptomatic Population
  • 5Risk Groups
  • 6Endoscopy: Performance and Polyp management
  • 7Pre-operative Diagnostics and Surgery
  • 8Adjuvant and Neoadjuvant Therapy
  • 9Management of Patients with Metastases and in the Palliative Situation
  • 10Follow-up Care
  • 11Quality Indicators
  • 12Abbildungsverzeichnis
  • 13Tabellenverzeichnis
    • 14Literaturverzeichnis

    Colorectal Cancer

    Chapters
    1 Information about this Guideline2 Introduction3 Prevention Asymptomatic Population4 Screening Asymptomatic Population5 Risk Groups6 Endoscopy: Performance and Polyp management7 Pre-operative Diagnostics and Surgery8 Adjuvant and Neoadjuvant Therapy9 Management of Patients with Metastases and in the Palliative Situation10 Follow-up Care11 Quality Indicators12 Abbildungsverzeichnis13 Tabellenverzeichnis14 Literaturverzeichnis
    PDF
    More
    CoverAll guidelines
    Chapters
    1 Information about this Guideline2 Introduction3 Prevention Asymptomatic Population4 Screening Asymptomatic Population5 Risk Groups6 Endoscopy: Performance and Polyp management7 Pre-operative Diagnostics and Surgery8 Adjuvant and Neoadjuvant Therapy9 Management of Patients with Metastases and in the Palliative Situation10 Follow-up Care11 Quality Indicators12 Abbildungsverzeichnis13 Tabellenverzeichnis14 Literaturverzeichnis
    CoverAll guidelines
    13

    Tabellenverzeichnis

    1Table 1Beteiligte Fachgesellschaften und OrganisationenOpen table2Table 2ArbeitsgruppenOpen table3Table 3Recommended Screening Programs for HNPCCOpen table4Table 4Classification Duodenal Polyposis Characteristics According to the Spigelman- Classification (modified according to [309])Open table5Table 5Overview of Guideline-Based Specific Procedural Quality Indicators of ColonoscopyOpen table6Table 6Follow-Up Intervals After PolypectomyOpen table7Table 7Staging of Colorectal CancerOpen table8Table 8Randomised Studies on First-Line Therapy With FOLFOXIRI In Unselected PatientsOpen table9Table 9Randomised Studies on First-Line Therapy With anti-EGFR Substances in RAS-wt PatientsOpen table10Table 10Summary of Meta-Analyses on Anti-EGFR Substances - OSOpen table11Table 11Summary of Meta-Analyses on Anti-EGFR Substances - PFSOpen table12Table 12Randomised Studies on First-Line Therapy With Bevacizumab In Unselected PatientsOpen table13Table 13Summary of Meta-Analyses On Bevacizumab - OSOpen table14Table 14Summary of Meta-Analyses On Bevacizumab - PFSOpen table15Table 15Randomised Studies on Second-Line Therapy With Anti-VEGF SubstancesOpen table16Table 16Randomised Studies on Second-Line Therapy With Anti-EGFR SubstancesOpen table17Table 17Programmed Examination for the Follow-Up of CRC UICC II or IIIOpen table
    ← AbbildungsverzeichnisLiteraturverzeichnis →